$SVRA News

Savara Inc. (SVRA) Reports Q1 Financial Results

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP At ATS 2026 International Conference

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Q1 EPS $(0.15) Misses $(0.14) Estimate

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim

Savara Announces New Employment Inducement Grant

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimmune Pulmonary Alveolar Proteinosis

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Q4 EPS $(0.13), Inline